Table A1.
Demographic and clinical data of all patients included into the study including Gleason score, radical or palliative initial therapy, pathological or clinical diagnosis, TNM classification PSA level before PSMA examination.
| Pt No | Age | Indication | GlS ** | R/P # | Primary Diagnosis | TNM $ | PSA before Scan (ng/mL) | Doubling Time PSA (Months) |
|---|---|---|---|---|---|---|---|---|
| 1 | 53 | Stage | 4 + 5 | P | 21.01.2014 | cTxN1M1 | 4.38 | n.d. |
| 2 | 65 | Rec | 5 + 3 | R | 01.02.2014 | pT3bN0Mx | 0.1 | >12.0 |
| 3 | 66 | Stage | 3 + 4 | P | 01.06.2014 | cTxN1M1 | 35.2 | |
| 4 | 65 | Rec | 4 + 3 | R | 12.04.2018 | pT3bN0Mx | 10.4 | 1.2 |
| 5 | 67 | Rec | 4 + 3 | R | 02.03.2018 | pT3aN0M0 | 1.41 | n.d. |
| 6 | 66 | Rec | 5 + 4 | R | 11.05.2016 | pT3bN0Mx | 1.73 | 4.7 |
| 7 | 78 | Stage | 5 + 5 | P | 27.03.2019 | cTxNxM1 | 10.2 | |
| 8 | 72 | Rec | 3 + 4 | R | 22.12.2015 | pT2aN0M0 | 1.54 | 2.0 |
| 9 | 56 | Stage * | 4 + 4 | R | 30.04.2019 | pT3bN1Mx | 25.9 | |
| 10 | 69 | Stage | 4 + 3 | P | 13.04.2018 | cT4N1M1 | 54.8 | n.d. |
| 11 | 72 | Rec | 4 + 3 | R | 30.11.2018 | pT2cN0Mx | 0.48 | n.d. |
| 12 | 76 | Rec | 4 + 5 | R(Rtx) | 23.05.2013 | cT2cNxM0 | 0.28 | >12.0 |
| 13 | 66 | Stage | 4 + 5 | P | 02.02.2012 | cTxNxM1 | 0.35 | n.d. |
| 14 | 59 | Rec | 3 + 3 | R(Rtx) | 04.06.2008 | cT2cNxM0 | 0.84 | >12.0 |
| 15 | 69 | Rec | 3 + 4 | R | 30.07.2019 | pT3bN1Mx | 9.39 | 4.1 |
| 16 | 68 | Rec | 3 + 4 | R | 17.10.2018 | pT3bN1Mx, | 0.1 | |
| 17 | 63 | Rec | 3 + 5 | R | 26.02.2013 | pT3cN1Mx | 5.99 | n.d. |
| 18 | 69 | Rec | 3 + 5 | R | 01.09.2017 | pT3bN0M0 | 5.68 | 10.0 |
| 19 | 68 | Rec | 4 + 3 | R | 08.04.2019 | pT2bN0Mx | 0.23 | |
| 20 | 81 | Stage | 3 + 3 | P | 18.04.2018 | cTxNxM1 | 29.6 | >12.0 |
| 21 | 67 | Rec | 4 + 3 | R | 25.05.2018 | pT3bN1Mx | 12.4 | n.d. |
| 22 | 71 | Stage | 4 + 5 | P | 29.03.2019 | cTxN1M1 | 7.2 | |
| 23 | 74 | Rec | 4 + 3 | R | 20.11.2018 | pT3bN0M0 | 0.2 | n.d. |
| 24 | 66 | Stage * | 4 + 3 | P | 29.05.2019 | cT3bN1Mx | 6.94 | >12.0 |
| 25 | 66 | Rec | 3 + 4 | R | 10.03.2015 | pT2aN0M0 | 1.6 | n.d. |
| 26 | 62 | Rec | 3 + 4 | R | 02.04.2014 | pT2CN0M0 | 0.12 | 9.0 |
| 27 | 87 | Stage | 4 + 4 | P | 18.03.2019 | cTxNxM1 | 228.0 | >12.0 |
| 28 | 59 | Rec | 3 + 3 | R | 03.08.2005 | pT2cN0Mx | 3.3 | 3.0 |
| 29 | 69 | Rec | 5 + 5 | R | 20.12.2018 | pT3bN1Mx | 0.14 | |
| 30 | 66 | Rec | 3 + 4 | R | 10.06.2016 | pT2cN0Mx | 0.02 | 5.0 |
| 31 | 76 | Stage * | 4 + 3 | R | 01.02.2019 | pT3bN0Mx | 6.63 | >12.0 |
Indication of PSMA scanning Stage: evaluation of disease extent and metabolic activity (before radical therapy * or palliative settings); Rec: evaluation of recurrence after radical therapy; GlS **: Gleason Score; R/P #: Radical or Palliative Therapy, previous or current; TNM $: pathologi-cal pTNM or clinical cTNM classification of PCa; R(Rtx): radical radiotherapy.